Braeburn Drug Patent Portfolio
Braeburn owns 1 orange book drug protected by 8 US patents Given below is the list of Braeburn's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10912772 | Opioid formulations | 26 Jul, 2032 | Active |
| US11110084 | Opioid formulations | 26 Jul, 2032 | Active |
| US11135215 | Opioid formulations | 26 Jul, 2032 | Active |
| US12161640 | Opioid formulations | 26 Jul, 2032 | Active |
| US9937164 | Opioid formulations | 26 Jul, 2032 | Active |
| US8236292 | Liquid depot formulations | 10 Jan, 2027 | Active |
| US8236755 | Opioid depot formulations | 31 Jul, 2026 | Active |
| US8545832 | Lipid depot formulations | 06 Jun, 2025 | Active |
Latest Legal Activities on Braeburn's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Braeburn.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 07 Feb, 2024 | US8236755 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 07 Feb, 2024 | US8236292 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 11 Oct, 2021 | US9937164 |
|
Recordation of Patent Grant Mailed
Critical
| 05 Oct, 2021 | US11135215 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 05 Oct, 2021 | US11135215 |
|
Email Notification
Critical
| 16 Sep, 2021 | US11135215 |
|
Issue Notification Mailed
Critical
| 15 Sep, 2021 | US11135215 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 07 Sep, 2021 | US11110084 |
|
Email Notification
Critical
| 07 Sep, 2021 | US11135215 |
|
Recordation of Patent Grant Mailed
Critical
| 07 Sep, 2021 | US11110084 |
|
Mail Response to 312 Amendment (PTO-271)
Critical
| 07 Sep, 2021 | US11135215 |
|
Application Is Considered Ready for Issue
Critical
| 01 Sep, 2021 | US11135215 |
| Dispatch to FDC | 01 Sep, 2021 | US11135215 |
|
Response to Amendment under Rule 312
Critical
| 01 Sep, 2021 | US11135215 |
|
Amendment after Notice of Allowance (Rule 312)
Critical
| 31 Aug, 2021 | US11135215 |
Braeburn's Family Patents
Braeburn Drug List
Given below is the complete list of Braeburn's drugs and the patents protecting them.
1. Brixadi
Brixadi is protected by 8 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10912772 | Opioid formulations |
26 Jul, 2032
(7 years from now)
| Active |
| US11110084 | Opioid formulations |
26 Jul, 2032
(7 years from now)
| Active |
| US11135215 | Opioid formulations |
26 Jul, 2032
(7 years from now)
| Active |
| US12161640 | Opioid formulations |
26 Jul, 2032
(7 years from now)
| Active |
| US9937164 | Opioid formulations |
26 Jul, 2032
(7 years from now)
| Active |
| US8236292 | Liquid depot formulations |
10 Jan, 2027
(1 year, 10 months from now)
| Active |
| US8236755 | Opioid depot formulations |
31 Jul, 2026
(1 year, 5 months from now)
| Active |
| US8545832 | Lipid depot formulations |
06 Jun, 2025
(3 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Brixadi's drug page